Patents Assigned to CHASE THERAPEUTICS CORPORATION
  • NK-1 antagonist compositions and methods for use in treating depression
    Patent number: 11813248
    Abstract: The present invention describes the combination of a NK1-antagonist with pramipexole or a pharmaceutically acceptable salt or solvate thereof, useful for treating depressive disorders, including major depressive disorder.
    Type: Grant
    Filed: February 14, 2022
    Date of Patent: November 14, 2023
    Assignee: CHASE THERAPEUTICS CORPORATION
    Inventors: Thomas N. Chase, Kathleen E. Clarence-Smith
  • NK-1 antagonist compositions and methods for use in treating depression
    Patent number: 11813247
    Abstract: The present invention describes the combination of a NK1-antagonist with pramipexole or a pharmaceutically acceptable salt or solvate thereof, useful for treating depressive disorders, including major depressive disorder.
    Type: Grant
    Filed: February 14, 2022
    Date of Patent: November 14, 2023
    Assignee: CHASE THERAPEUTICS CORPORATION
    Inventors: Thomas N. Chase, Kathleen E. Clarence-Smith
  • Compositions and methods for treating synucleinopathies
    Patent number: 11547700
    Abstract: The present invention describes the use of a 5HT3-antagonist, in combination with a 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine, to reduce adverse effects and to facilitate the neuroprotective treatment of a patient suffering from a synucleinopathic disorder to enable a therapeutically effective 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine daily dose without the dose-limiting adverse effects caused by pramipexole when administered alone.
    Type: Grant
    Filed: August 31, 2020
    Date of Patent: January 10, 2023
    Assignee: CHASE THERAPEUTICS CORPORATION
    Inventors: Thomas N. Chase, Kathleen E. Clarence-Smith
  • NK-1 ANTAGONIST COMPOSITIONS AND METHODS FOR USE IN TREATING DEPRESSION
    Publication number: 20220168281
    Abstract: The present invention describes the combination of a NK1-antagonist with pramipexole or a pharmaceutically acceptable salt or solvate thereof, useful for treating depressive disorders, including major depressive disorder.
    Type: Application
    Filed: February 14, 2022
    Publication date: June 2, 2022
    Applicant: CHASE THERAPEUTICS CORPORATION
    Inventors: Thomas N. CHASE, Kathleen E. CLARENCE-SMITH
  • NK-1 ANTAGONIST COMPOSITIONS AND METHODS FOR USE IN TREATING DEPRESSION
    Publication number: 20220160683
    Abstract: The present invention describes the combination of a NK1-antagonist with pramipexole or a pharmaceutically acceptable salt or solvate thereof, useful for treating depressive disorders, including major depressive disorder.
    Type: Application
    Filed: February 14, 2022
    Publication date: May 26, 2022
    Applicant: CHASE THERAPEUTICS CORPORATION
    Inventors: Thomas N. CHASE, Kathleen E. CLARENCE-SMITH
  • Pharmaceutical combination and its use for treating synucleinopathties
    Patent number: 11318122
    Abstract: The present invention describes the combination of a 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine or of a pharmaceutically acceptable salt or solvate thereof with fluoxetine or a pharmaceutically acceptable salt or solvate thereof, for use for treating a synucleinopathy such as Parkinson's disease, Lewy body disease, mutations in the glucocerebrosidase gene, or multiple system atrophy.
    Type: Grant
    Filed: April 11, 2018
    Date of Patent: May 3, 2022
    Assignee: CHASE THERAPEUTICS CORPORATION
    Inventors: Thomas N. Chase, Kathleen E. Clarence-Smith
  • DOMPERIDONE COMPOSITIONS AND METHODS FOR TREATING DEPRESSION
    Publication number: 20220071976
    Abstract: The present invention describes the combination of domperidone with pramipexole or a pharmaceutically acceptable salt or solvate thereof, useful for treating depressive disorders, including major depressive disorder.
    Type: Application
    Filed: December 12, 2019
    Publication date: March 10, 2022
    Applicant: CHASE THERAPEUTICS CORPORATION
    Inventors: Thomas N. CHASE, Kathleen E CLARENCE-SMITH
  • NK-1 antagonist compositions and methods for use in treating depression
    Patent number: 11266633
    Abstract: The present invention describes the combination of a NK1-antagonist with pramipexole or a pharmaceutically acceptable salt or solvate thereof, useful for treating depressive disorders, including major depressive disorder.
    Type: Grant
    Filed: June 28, 2018
    Date of Patent: March 8, 2022
    Assignee: CHASE THERAPEUTICS CORPORATION
    Inventors: Thomas N. Chase, Kathleen E. Clarence-Smith
  • DOMPERIDONE ANTINEURODEGENERATIVE COMBINATIONS AND USE
    Publication number: 20220000854
    Abstract: A pharmaceutical combination comprising domperidone, a 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine and at least one of fluoxetine, zonisamide or a statin, for the treatment of protein misfolding neurodegenerative diseases.
    Type: Application
    Filed: December 3, 2019
    Publication date: January 6, 2022
    Applicant: CHASE THERAPEUTICS CORPORATION
    Inventors: Thomas N. CHASE, Kathleen E CLARENCE-SMITH
  • ANTI-NEURODEGENERATIVE COMBINATIONS AND USE FOR TREATMENT OF NEURODEGENERATIVE DISEASES
    Publication number: 20210393595
    Abstract: The present invention provides a combination of a 5HT3-antagonist and/or a NK-1 antagonist with 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine and with fluoxetine or a pharmaceutically acceptable salt or solvate thereof, zonisamide or a pharmaceutically acceptable salt or solvate thereof, or a statin or a pharmaceutically acceptable salt or solvate thereof, for use for treating a protein misfolding neurodegenerative disease such as Alzheimer's disease, Lewy body disease, Parkinson's disease, or Huntington's disease.
    Type: Application
    Filed: September 25, 2019
    Publication date: December 23, 2021
    Applicant: CHASE THERAPEUTICS CORPORATION
    Inventors: Thomas N. CHASE, Kathleen E. CLARENCE-SMITH
  • COMPOSITION AND USE FOR THE TREATMENT OF PARKINSON'S DISEASE AND RELATED DISORDERS
    Publication number: 20210338652
    Abstract: The present invention provides a pharmaceutical combination comprising an inhibitor of dopamine agonist adverse effects and a dopamine agonist, for treating Parkinson's disease and Parkinson's disease-related disorders.
    Type: Application
    Filed: September 24, 2019
    Publication date: November 4, 2021
    Applicant: CHASE THERAPEUTICS CORPORATION
    Inventors: Thomas N. CHASE, Kathleen E. CLARENCE-SMITH
  • NK1-antagonist combination and method for treating synucleinopathies
    Patent number: 11160809
    Abstract: The present invention describes the use of a NK1-antagonist, in combination with 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine, to facilitate the treatment of a patient suffering from a synucleinopathy by enabling a therapeutically effective 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine daily dose to act without the typical adverse effects caused by pramipexole dihydrochloride monohydrate when administered alone.
    Type: Grant
    Filed: April 9, 2018
    Date of Patent: November 2, 2021
    Assignee: CHASE THERAPEUTICS CORPORATION
    Inventors: Thomas N. Chase, Kathleen E. Clarence-Smith
  • COMPOSITIONS AND METHODS FOR TREATING SYNUCLEINOPATHIES
    Publication number: 20200397761
    Abstract: The present invention describes the use of a 5HT3-antagonist, in combination with a 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine, to reduce adverse effects and to facilitate the neuroprotective treatment of a patient suffering from a synucleinopathic disorder to enable a therapeutically effective 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine daily dose without the dose-limiting adverse effects caused by pramipexole when administered alone.
    Type: Application
    Filed: August 31, 2020
    Publication date: December 24, 2020
    Applicant: CHASE THERAPEUTICS CORPORATION
    Inventors: Thomas N. Chase, Kathleen E. Clarence-Smith
  • COMPOSITIONS AND METHOD FOR TREATING DEPRESSION
    Publication number: 20200375957
    Abstract: The present invention describes the combination of a 5HT3-antagonist with pramipexole to reduce or eliminate the adverse effects associated with the use of pramipexole and to enable the use of high doses of pramipexole, useful for treating depressive disorders such as major depressive disorder.
    Type: Application
    Filed: April 23, 2018
    Publication date: December 3, 2020
    Applicant: CHASE THERAPEUTICS CORPORATION
    Inventors: Thomas N. CHASE, Kathleen E. CLARENCE-SMITH
  • PHARMACEUTICAL COMBINATION AND ITS USE FOR TREATING SYNUCLEINOPATHIES
    Publication number: 20200375956
    Abstract: The present invention describes the combination of a 6-propylamino-4,5,6,7-tetrahydro-1,3- benzothiazole-2-amine or of a pharmaceutically acceptable salt or solvate thereof with fluoxetine or a pharmaceutically acceptable salt or solvate thereof, for use for treating a synucleinopathy such as Parkinson's disease, Lewy body disease, mutations in the glucocerebrosidase gene, or multiple system atrophy.
    Type: Application
    Filed: April 11, 2018
    Publication date: December 3, 2020
    Applicant: CHASE THERAPEUTICS CORPORATION
    Inventors: Thomas N. CHASE, Kathleen E. CLARENCE-SMITH
  • Compositions and methods for treating synucleinopathies
    Patent number: 10799484
    Abstract: The present invention describes the use of a 5HT3-antagonist, in combination with a 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine, to reduce adverse effects and to facilitate the neuroprotective treatment of a patient suffering from a synucleinopathic disorder to enable a therapeutically effective 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine daily dose without the dose-limiting adverse effects caused by pramipexole when administered alone.
    Type: Grant
    Filed: March 26, 2018
    Date of Patent: October 13, 2020
    Assignee: CHASE THERAPEUTICS CORPORATION
    Inventors: Thomas N. Chase, Kathleen E. Clarence-Smith
  • NK-1 ANTAGONIST COMPOSITIONS AND METHODS FOR USE IN TREATING DEPRESSION
    Publication number: 20200147053
    Abstract: The present invention describes the combination of a NK1-antagonist with pramipexole or a pharmaceutically acceptable salt or solvate thereof, useful for treating depressive disorders, including major depressive disorder.
    Type: Application
    Filed: June 28, 2018
    Publication date: May 14, 2020
    Applicant: CHASE THERAPEUTICS CORPORATION
    Inventors: Thomas N. CHASE, Kathleen E. CLARENCE-SMITH
  • NK1-ANTAGONIST COMBINATION AND METHOD FOR TREATING SYNUCLEINOPATHIES
    Publication number: 20200147097
    Abstract: The present invention describes the use of a NK1-antagonist, in combination with 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine, to facilitate the treatment of a patient suffering from a synucleinopathy by enabling a therapeutically effective 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine daily dose to act without the typical adverse effects caused by pramipexole dihydrochloride monohydrate when administered alone.
    Type: Application
    Filed: April 9, 2018
    Publication date: May 14, 2020
    Applicant: CHASE THERAPEUTICS CORPORATION
    Inventors: Thomas N CHASE, Kathleen E. CLARENCE-SMITH
  • PHARMACEUTICAL COMBINATIONS OF ZONISAMIDE AND PRAMIPEXOLE, AND RELATED METHODS, FOR TREATING SYNUCLEINOPATHIES
    Publication number: 20200138792
    Abstract: The present invention relates to a combination of zonisamide with pramipexole or a pharmaceutically acceptable salt or solvate of pramipexole for treating a synucleinopathy.
    Type: Application
    Filed: May 23, 2018
    Publication date: May 7, 2020
    Applicant: CHASE THERAPEUTICS CORPORATION
    Inventors: Thomas N. CHASE, Kathleen E. CLARENCE-SMITH
  • STATIN COMPOSITIONS AND METHODS FOR USE IN TREATING SYNUCLEINOPATHIES
    Publication number: 20200113899
    Abstract: The present invention describes pharmaceutical combinations, compositions, and methods comprising a statin and 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine or a pharmaceutically acceptable salt and/or solvate thereof, that are useful for the treatment of synucleinopathic disorders.
    Type: Application
    Filed: July 3, 2018
    Publication date: April 16, 2020
    Applicant: CHASE THERAPEUTICS CORPORATION
    Inventors: Thomas N. CHASE, Kathleen E. CLARENCE-SMITH